Luminespib and AZ5104 are effective antithrombotic drugs via targeting the platelet Ero1α-PDI pathway
Science Advances · 2026
DOI: 10.1126/sciadv.aeg2095 ↗Kurz gefasst
Fachartikel in der Zeitschrift Science Advances, 2026. Verfasst von Shuo Sun und 12 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory of Biomacromolecules, Institute of Biophysics, Chinese Academy of Sciences, Beijing 100101, China. Hauptthemen laut MEDLINE: Blood Platelets, Fibrinolytic Agents, Protein Disulfide-Isomerases, Signal Transduction. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 59 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: National Natural Science Foundation of China, Chinese Academy of Sciences, National key R&D program of China.
Abstract (Originalsprache)
The platelet-surface Ero1α–protein disulfide isomerase (PDI) system is essential for integrin αIIbβ3 activation and platelet aggregation. Targeting the functional interplay between Ero1α and PDI emerges as a promising antithrombotic strategy. Using a tiered high-throughput screen, we identified two clinical-stage compounds, Luminespib and AZ5104, as selective inhibitors of the Ero1α-PDI interaction. They bind a hydrophobic pocket in the PDI b ʹ domain, inhibiting the pathway in biochemical and cellular assays without affecting other PDI family members. The antiplatelet effects of Luminespib and AZ5104 were abolished in megakaryocyte-specific Pdi or Ero1a knockout mice, confirming on-target specificity. Mechanistically, they concurrently inhibit Ero1α-PDI–driven extracellular integrin activation and intracellular Ca 2+ signaling. Both compounds potently reduced arterial thrombosis in mice without prolonging bleeding time. Our work establishes Luminespib and AZ5104 as clinical-stage antithrombotic agents that target the platelet Ero1α-PDI system, offering an effective strategy to achieve potent antithrombosis without compromising hemostasis.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- State Key Laboratory of Biomacromolecules, Institute of Biophysics, Chinese Academy of Sciences, Beijing 100101, China.
- College of Life Sciences, University of Chinese Academy of Sciences, Beijing 100049, China.
- Department of Pharmacology, School of Basic Medicine, Tongji Medical College and State Key Laboratory for Diagnosis and Treatment of Severe Zoonotic Infectious Diseases, Huazhong University of Science and Technology, Wu…
- Department of Physiology and Pathophysiology, School of Basic Medical Sciences, Peking University Health Science Center, Beijing 100191, China.
- State Key Laboratory of Vascular Homeostasis and Remodeling, Peking University, Beijing 100191, China.
- The Key Laboratory for Drug Target Researches and Pharmacodynamic Evaluation of Hubei Province, Wuhan, Hubei 430030, China.
ORCID-Profile: Shuo Sun, Weibin Gong, Keyu Lv, Xi Wang, Xi Wang, Yi Fu, Tao Jiang, Chao Fang, Lei Wang
Förderung
- National Natural Science Foundation of China
- Chinese Academy of Sciences
- National key R&D program of China
- Shanghai Guangci Translationnal Medical Research Development Foundation
Zitieren
APA
Sun, S., Gong, W., Lv, K., Zhao, X., Tang, W., Wang, X., Liu, P., Wang, X., Wang, X., Fu, Y., Jiang, T., Fang, C., & Wang, L. (2026). Luminespib and AZ5104 are effective antithrombotic drugs via targeting the platelet Ero1α-PDI pathway. Science Advances. https://doi.org/10.1126/sciadv.aeg2095
Vancouver
Sun S, Gong W, Lv K, Zhao X, Tang W, Wang X, et al. Luminespib and AZ5104 are effective antithrombotic drugs via targeting the platelet Ero1α-PDI pathway. Science Advances. 2026. doi:10.1126/sciadv.aeg2095
BibTeX
@article{Sun2026,
author = {Sun, Shuo and Gong, Weibin and Lv, Keyu and Zhao, Xuqian and Tang, Wenyong and Wang, Xi'e and Liu, Ping and Wang, Xi and Wang, Xi and Fu, Yi and Jiang, Tao and Fang, Chao and Wang, Lei},
title = {Luminespib and AZ5104 are effective antithrombotic drugs via targeting the platelet Ero1α-PDI pathway},
journal = {Science Advances},
year = {2026},
doi = {10.1126/sciadv.aeg2095}
}
EUVIMED